SILVITELLI, MARIA
SILVITELLI, MARIA
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study
2025 Gentile, I.; Viceconte, G.; Cuccurullo, F.; Pietroluongo, D.; D'Agostino, A.; Silvitelli, M.; Mercinelli, S.; Scotto, R.; Grimaldi, F.; Palmieri, S.; Gravetti, A.; Trastulli, F.; Moccia, M.; Buonomo, A. R.
Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
2023 Gentile, I.; Foggia, M.; Silvitelli, M.; Sardanelli, A.; Cattaneo, L.; Viceconte, G.
Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study)
2025 Gentile, I.; Scotto, R.; Scirocco, M. M.; Di Brizzi, F.; Cuccurullo, F.; Silvitelli, M.; Ametrano, L.; Alfe, F. A.; Pietroluongo, D.; Irace, I.; Chiariello, M.; De Felice, N.; Severino, S.; Viceconte, G.; Schiano Moriello, N.; Maraolo, A. E.; Buonomo, A. R.; Giaccone, A.
Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case–control study (SAVALO Study)(BMC Infect Dis., (2024), 24, 1434, 10.1186/s12879-024-10303-5)
2025 Gentile, I.; Giaccone, A.; Scirocco, M. M.; Di Brizzi, F.; Cuccurullo, F.; Silvitelli, M.; Ametrano, L.; Alfe, F. A.; Pietroluongo, D.; Irace, I.; Chiariello, M.; De Felice, N.; Severino, S.; Viceconte, G.; Moriello, N. S.; Maraolo, A. E.; Buonomo, A. R.; Scotto, R.
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study | 1.1 Articolo in rivista | 2025 | Gentile, I.; Viceconte, G.; Cuccurullo, F.; Pietroluongo, D.; D'Agostino, A.; Silvitelli, M.; Mercinelli, S.; Scotto, R.; Grimaldi, F.; Palmieri, S.; Gravetti, A.; Trastulli, F.; Moccia, M.; Buonomo, A. R. | |
| Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab | 1.1 Articolo in rivista | 2023 | Gentile, I.; Foggia, M.; Silvitelli, M.; Sardanelli, A.; Cattaneo, L.; Viceconte, G. | |
| Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study) | 1.1 Articolo in rivista | 2025 | Gentile, I.; Scotto, R.; Scirocco, M. M.; Di Brizzi, F.; Cuccurullo, F.; Silvitelli, M.; Ametrano, L.; Alfe, F. A.; Pietroluongo, D.; Irace, I.; Chiariello, M.; De Felice, N.; Severino, S.; Viceconte, G.; Schiano Moriello, N.; Maraolo, A. E.; Buonomo, A. R.; Giaccone, A. | |
| Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case–control study (SAVALO Study)(BMC Infect Dis., (2024), 24, 1434, 10.1186/s12879-024-10303-5) | 1.7 Commento, erratum, replica e simili | 2025 | Gentile, I.; Giaccone, A.; Scirocco, M. M.; Di Brizzi, F.; Cuccurullo, F.; Silvitelli, M.; Ametrano, L.; Alfe, F. A.; Pietroluongo, D.; Irace, I.; Chiariello, M.; De Felice, N.; Severino, S.; Viceconte, G.; Moriello, N. S.; Maraolo, A. E.; Buonomo, A. R.; Scotto, R. |